The Impact of Hyperglycemia on Risk of Severe Infections during Early Period of Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma

Table 1

Univariate analysis of risk factor for early severe infections during induction therapy (𝑛=155).

Variable	Infection rates; 18.1% (28/155)	𝑃 value	OR (95% CI)
Gender
Male	17.9% (14/78)	1.000	1.016 (0.448–2.303)
Female	18.2% (14/77)
Age
<65 years	21.6% (22/102)	0.129	0.464 (0.176–1.227)
≥65 years	11.3% (6/53)
ECOG performance status
<2	12.3% (15/122)	0.001	4.637 (1.918–11.211)
≥2	39.4% (13/33)
Immunophenotype
Others	19.7% (23/117)	0.470	0.619 (0.218–1.761)
Light chain	13.2% (5/38)
Body mass index
<25 kg/m^2	20.9% (23/110)	0.174	0.473 (0.168–1.334)
≥25 kg/m^2	11.1% (5/45)
ISS
I-II	10.3% (10/97)	0.002	3.915 (1.658–9.242)
III	31.0% (18/58)
Serum creatinine, mg/dL
<2.0	14.0% (17/121)	0.022	2.926 (1.210–7.073)
≥2.0	32.4% (11/34)
Blood sugar during induction therapy
<200 mg/dL	12.6% (17/135)	<0.001	8.484 (3.068–23.460)
≥200 mg/dL	55.0% (11/20)
Early response (after 2 cycles)
≥PR	15.0% (15/100)	0.196	1.754 (0.765–4.021)
<PR	23.6% (13/55)
Neutropenia during induction therapy
≥1,000/𝜇L	17.6% (22/125)	0.793	1.170 (0.428–3.201)
<1,000/𝜇L	20.0% (6/30)
Lymphopenia during induction therapy
≥500/𝜇L	12.9% (14/108)	0.022	2.848 (1.229–6.600)
<500/𝜇L	29.8% (14/47)
Treatment with novel agents
Yes	18.9% (26/137)	0.531	1.874 (0.405–8.660)
No	11.1% (2/18)

ECOG: Eastern Cooperative Oncology Group; ISS: International Staging System; PR: partial response.